DOCSLIB.ORG

Cobicistat + Elvitegravir + Emtricitabine + Tenofovir Alfenamide

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cobicistat + Elvitegravir + Emtricitabine + Tenofovir Alfenamide 20, AVENUE APPIA – CH-1211 GENEVA 27 – SWITZERLAND – TEL CENTRAL +41 22 791 2111 – FAX CENTRAL +41 22 791 3111 – WWW.WHO.INT Comments on EML application : cobicistat + elvitegravir + emtricitabine + tenofovir alfenamide The WHO HIV Department does not support the addition of the formulation cobicistat + elvitegravir + emtricitabine + tenofovir alfenamide in 2017 WHO Model List of Essential Medicines for treatment of HIV infection for the following reasons Cobicisitat( COBI), elvitegravir (EVG) and tenofovir alfenamide (TAF) are not included as options in 2016 WHO consolidated guidelines on use of antiretrovirals for treating and preventing of HIV infection 1. A recent WHO systematic review comparing the use of integrase inhibitors in 1st line showed that dolutegravir and raltegravir were superior to elvitegravir/cobicistat (EVG/COBI) in terms of viral suppression, CD4 recovery and risk of treatment discontinuation.2 There are important concerns with the use of TAF and EVG/COBI in TB co-infection. EGV/COBI has important and well documented drug interactions with rifampicin and must not be co-administrated, as will result in loss of its antiviral effect3 4 Regarding TAF, there are no published data available on the pharmacokinetics and real-world efficacy of TAF in TB- coinfected patients. While the current available tenofovir prodrug (tenofovir disoproxil fumarate or TDF) does not require dose-adjustment if co-administered with rifampicin, TAF is currently contraindicated by the originator in patients being treated with rifampicin, as significant drug interaction is predicted based on pK modelling 56. Data on the potential for TAF dose adjustment are awaited. There are very limited data available on the safety of EVG/COBI and TAF during pregnancy. Preliminary pK studies in pregnant women showed that EVG and COBI exposure are substantially lower during pregnancy compared to postpartum and standard doses may not be adequate for sustained viral suppression 7 8. Despite preclinical toxicity studies with TAF in pregnancy didn´t reveal concerns, preliminary pK data in humans showed a 5-fold higher intracellular tenofovir concentration with TAF when compared with TDF9. It might lower the risk of mother-to-child transmission of HIV, but it can also increase the risk of birth abnormalities. There is no data are available on placental or breast milk passage of EVG/COBI or TAF in 1 World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2nd Edition Geneva: WHO; 2016. 2 Kanters S, Vitoria M, Doherty M, Mills EJ. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet HIV, 2016; 3:e510-20. 3 Lee JSF, Calmy A, Andrieux-Meyer I, Ford N. Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings. HIV/AIDS (Auckland, NZ). 2012;4:5-15. 4 Evitegravir [package insert]. Food and Drug Administration. 2015. Available at http://www.accessdata.fda.gov/ drugsatfda_docs/label/2015/203093s002lbl.pdf. 5 Genvoya [package insert]. Food and Drug Administration. 2015. Available at: http://www.accessdata.fda.gov/ drugsatfda_docs/label/2015/207561s000lbl.pdf 6 Ray AS, Fordyce MW, Hitchcock MJM.Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. Antiviral Res, 2016, 125:63-70 7 Schalkwijk S, Colbers A, Konopnicki D, et al. First reported use of elvitegravir and cobicistat during pregnancy. AIDS. 2016;30(5):807-808. 8 Best BM, Capparelli EV, Stek A, Acosta EP, Smith E and IMPAACT 1026a Protocol Team. Elvitegravir/Cobicistat Pharmacokinetics in Pregnancy and Postpartum. Abstract #755. CROI 2017, Seattle; 2017 9 Vitoria M, Hill AM, Ford NP, Doherty M, Khoo SH, Pozniak AL. Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know? J Int AIDS Soc. 2016; 19(1): 20504. Page 2 humans. Until results from pK and large database of TAF- and EVG/COBI treated pregnant women have been analysed, it is not possible to evaluate the real safety risk of using these drugs in pregnant/breastfeed women. Despite lesser detrimental effects on bone and renal lab markers with TAF use, there is no difference in adverse event rates in major TAF and TDF comparative studies1011. An unpublished meta-analysis of 10 clinical trials compared TDF- and TAF-based regimens, which together comprised almost 7000 participants and more than 8000 patient-years of follow-up. This metanalysis did not reveal statistically significant differences in virological outcomes, adverse events, lab abnormalities, or deaths, and only showed differences when specific bone and renal laboratorial parameters were compared. 12 Data on the effectiveness of TAF in severely immunocompromised HIV patients is also missing: none of the available studies had mean/median baseline CD4 cell counts below 350 cells/mm3. Important to emphasize that the median CD4 cell count at ART initiation among PLHIV in all regions of the globe, including high income countries, are still below this threshold.13 14 15 16 17 18 19 Data on EVG/COBI and TAF use in adolescents (12-18 years old) are available only for a comparatively small sample (50 participants in total), and only for 48 weeks of study follow-up20. Clinical studies in children younger than 12 years old are still ongoing. In conclusion, the recommendation to use therapeutic regimens containing COBI, EVG and TAF as a standard options for low- and middle-income countries is viewed by WHO as premature and requires more data for tuberculosis, pregnancy, children and PLHIV with severe immunosuppression. 10 Sax P, Zolopa A, Brar I et al. 2014. Tenofovir alafenamide vs tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomised phase 2 study. J Acquire Immune Defic Syndr, 67(1), pp. 52-58 11 Sax P, Wohl D, Yin M et al. 2015. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for inititial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. The Lancet, 385, pp 2606-2615 12 Gotham D, Hill A, Pozniak A L. Candidates for inclusion in a Universal Antiretroviral Regimen: Tenofovir Alafenamide. Curr Opin HIV AIDS, 2017 (submitted for publication). 13 Mills A, Crofoot G, McDonald C, Shalit P, Flamm JA, Gathe J, et al. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study. J Acquir Immune Defic Syndr. 2015;69(4):439–45. 14 Sax PE, Zolopa A, Brar I, Elion R, Ortiz R, Post F, et al. Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy: A Randomized Phase 2 Study. J Acquir Immune Defic Syndr. 2014;67:52–8. 15 Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385(9987):2606–15. 16 Orkin C. Switching from rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks. In: HIV Glasgow. Glasgow; 2016. 17 Gallant JE, Daar ES, Raffi F, Brinson C, Ruane P, DeJesus E, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, activ. 3(4):e158--e165. 18 Raffi F. Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-infected, virologically suppressed adults. In: HIV Glasgow. Glasgow; 2016 19 Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis. 2016 Nov;16(1):43–52. 20 Gaur AH, Kizito H, Prasitsueubsai W, Rakhmanina N, Rassool M, et al. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial The Lancet HIV, Volume 3, Issue 12, December 2016, Pages e561-e568 .
Load more

Recommended publications
  • PATIENT INFORMATION STRIBILD® (STRY-Bild) (Elvitegravir, Cobicistat
    PATIENT INFORMATION STRIBILD® (STRY-bild) (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) tablets Important: Ask your healthcare provider or pharmacist about medicines that should not be taken with STRIBILD. For more information, see the section “What should I tell my healthcare provider before taking STRIBILD?” What is the most important information I should know about STRIBILD? STRIBILD can cause serious side effects, including: • Worsening of Hepatitis B infection. If you have hepatitis B virus (HBV) infection and take STRIBILD, your HBV may get worse (flare-up) if you stop taking STRIBILD. A “flare-up” is when your HBV infection suddenly returns in a worse way than before. o Do not run out of STRIBILD. Refill your prescription or talk to your healthcare provider before your STRIBILD is all gone. o Do not stop taking STRIBILD without first talking to your healthcare provider. o If you stop taking STRIBILD, your healthcare provider will need to check your health often and do blood tests regularly for several months to check your HBV infection. Tell your healthcare provider about any new or unusual symptoms you may have after you stop taking STRIBILD. See “What are the possible side effects of STRIBILD?” for more information about side effects. What is STRIBILD? STRIBILD is a prescription medicine that is used without other antiretroviral medicines to treat Human Immunodeficiency Virus-1 (HIV-1) in people 12 years of age and older: • who have not received anti-HIV-1 medicines in the past, or • to replace their current anti-HIV-1 medicines: o in people who have been on the same anti-HIV-1 medicine regimen for at least 6 months, and o who have an amount of HIV-1 in their blood (this is called “viral load”) that is less than 50 copies/mL, and o have never failed past HIV-1 treatment.
    [Show full text]
  • Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide
    PATIENT & CAREGIVER EDUCATION Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Genvoya Brand Names: Canada Genvoya Warning Hepatitis B has gotten worse when this drug was stopped in some people with hepatitis B. Close follow-up for a few months is needed when therapy is stopped in people who have hepatitis B. Do not stop giving this drug to your child without calling your child’s doctor. Hepatitis B testing needs to be done as you were told by the doctor. Talk with the doctor. Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide 1/9 What is this drug used for? It is used to treat HIV infection. What do I need to tell the doctor BEFORE my child takes this drug? If your child is allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell the doctor about the allergy and what signs your child had. If your child has any of these health problems: Kidney disease or liver disease. If your child takes any drugs (prescription or OTC, natural products, vitamins) that must not be taken with this drug, like certain drugs that are used for high cholesterol, migraines, or mood problems. There are many drugs that must not be taken with this drug. If your child is taking any other drugs to treat HIV. If your child is pregnant: Do not give this drug to your child during pregnancy.
    [Show full text]
  • EVOTAZ (Atazanavir Or Cobicistat) to Pregnant Rats and Rabbits (See Data)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Assess creatinine clearance (CLcr) before initiating treatment. Consider These highlights do not include all the information needed to use EVOTAZ alternative medications that do not require dosage adjustments in patients safely and effectively. See full prescribing information for EVOTAZ. with renal impairment. (5.3) • When cobicistat, a component of EVOTAZ, is used in combination with a EVOTAZ (atazanavir and cobicistat) tablet, for oral use tenofovir disoproxil fumarate (tenofovir DF)-containing regimen, cases of Initial U.S. Approval: 2015 acute renal failure and Fanconi syndrome have been reported. (5.4) • When used with tenofovir DF, assess urine glucose and urine protein at ---------------------------RECENT MAJOR CHANGES--------------------------­ baseline and monitor CLcr, urine glucose, and urine protein. Monitor serum Indications and Usage phosphorus in patients with or at risk for renal impairment. Coadministration Indications (1.1) 07/2020 with tenofovir DF is not recommended in patients with CLcr below 70 Dosage and Administration mL/min or in patients also receiving a nephrotoxic agent. (5.4) Laboratory Testing Prior to Initiation and During • Chronic kidney disease has been reported during postmarketing surveillance Treatment with EVOTAZ (2.1) 04/2020 in patients with HIV-1 infection treated with atazanavir, with or without Recommended Dosage (2.2) 07/2020 ritonavir. Consider alternatives in patients at high risk for renal disease or Not Recommended During Pregnancy (2.5) 04/2020 with preexisting renal disease. Monitor renal laboratory tests prior to therapy Contraindications (4) 04/2020 and during treatment with EVOTAZ. Consider discontinuation of EVOTAZ Warnings and Precautions in patients with progressive renal disease. (5.5) Immune Reconstitution Syndrome (5.11) 07/2020 • Nephrolithiasis and cholelithiasis have been reported.
    [Show full text]
  • Evotaz, INN-Atazanavir/Cobicistat
    EMA/391330/2015 Summary of the risk management plan (RMP) for Evotaz (atazanavir/cobicistat) This is a summary of the risk management plan (RMP) for Evotaz, which details the measures to be taken in order to ensure that Evotaz is used as safely as possible. For more information on RMP summaries, see here. This RMP summary should be read in conjunction with the EPAR summary and the product information for Evotaz, which can be found on Evotaz’s EPAR page. Overview of disease epidemiology Evotaz is an antiviral medicine used in combination with other medicines to treat adults infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS). HIV attacks the immune system (the body’s natural defences against infection) and weakens it by destroying a type of white blood cells called CD4 T-cells, which protect the body against infection caused by bacteria, viruses and other germs. If left untreated, the HIV virus multiplies and the body starts losing its ability to fight infection and disease. In 2012 over 35 million people were living with HIV, increased from 34 million in 2011 (including 900,000 in Western and Central Europe and 1.4 million in Eastern Europe and Central Asia). In 2012, about 2.3 million people were newly infected with HIV. In 2011, 1.7 million people died of AIDS, including 7,900 in Western and Central Europe and 92,000 in Eastern Europe and Central Asia. There is no cure for HIV, but early and effective treatment can reduce HIV in the blood and keep it at a low level.
    [Show full text]
  • Management of Hiv Infection
    MANAGEMENT OF HIV INFECTION Federal Bureau of Prisons Clinical Guidance September 2018 Clinical guidance is made available to the public for informational purposes only. The Federal Bureau of Prisons (BOP) does not warrant this guidance for any other purpose, and assumes no responsibility for any injury or damage resulting from the reliance thereof. Proper medical practice necessitates that all cases are evaluated on an individual basis and that treatment decisions are patient-specific. Referenced Program Statement versions within this document are for informational purposes only. Please refer to the most current version of the referenced Program Statement. Consult the BOP Health Management Resources Web page to determine the date of the most recent update to this document: http://www.bop.gov/resources/health_care_mngmt.jsp Federal Bureau of Prisons Management of HIV Infection Clinical Guidance September 2018 WHAT’S NEW IN THIS DOCUMENT? This document updates the December 2017 version of the BOP Clinical Guidance on the Management of HIV Infection. Treatment information throughout this document was updated to be in line with the Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents issued by the Department of Health and Human Services (DHHS) in 2018. NOTEWORTHY CHANGES INCLUDE REVISIONS IN THE FOLLOWING AREAS: • INDICATIONS FOR HIV TESTING: An opt out strategy of voluntary testing for HIV infection is recommended for all inmates, regardless of sentencing status, including new intakes and those already established in the population who have not declined testing. • MENINGOCOCCAL VACCINE: Adults with HIV infection who have not been previously vaccinated should receive a 2-dose primary series of MenACWY (MCV4), available as Menactra® or Menveo®, at least 2 months apart, and then revaccinated every 5 years.
    [Show full text]
  • Cobicistat (Tybost)
    © National HIV Curriculum PDF created September 28, 2021, 11:52 am Cobicistat (Tybost) Table of Contents Cobicistat Tybost Summary Drug Summary Key Clinical Trials Key Drug Interactions Drug Summary Cobicistat is a pharmacokinetic booster that blocks the cytochrome P450 3A4 (CYP3A4) enzyme, resulting in decreased metabolism and increased concentration of many other medications. As a component of antiretroviral therapy, cobicistat is used to increase the levels of certain antiviral agents, including elvitegravir, atazanavir, and darunavir. Cobicistat does not have anti-HIV activity, unlike ritonavir, the other pharmacokinetic booster used as part of antiretroviral therapy. Cobicistat is also available in several coformulated products: atazanavir-cobicistat, darunavir-cobicistat, elvitegravir-cobicistat-tenofovir alafenamide-emtricitabine, elvitegravir-cobicistat-tenofovir DF-emtricitabine, and darunavir-cobicistat- tenofovir alafenamide-emtricitabine. For persons needing a twice-daily protease inhibitor, cobicistat should not be used as the booster. Cobicistat is a nonselective enzymatic blocker that has the potential to cause significant drug interactions. The major side effects associated with cobicistat are gastrointestinal symptoms. Cobicistat blocks renal tubular secretion of creatinine and typically raises serum creatinine by about 0.1 mg/dL; this increase in serum creatinine does not represent a decrease in actual creatinine clearance. It is not recommended for use in combination with tenofovir DF in patients with an estimated creatinine
    [Show full text]
  • Selected Properties of Cobicistat Other Names GS-9350, Tybost
    Selected Properties of Cobicistat Other names GS-9350, Tybost® Combination formulation: • Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir) • Prezcobix (darunavir 800 mg/cobicistat 150 mg); Rezolsta (EU trade name) Manufacturer Gilead Sciences Canada Inc. (Stribild®, Tybost®); Janssen Inc (Prezcobix®) Pharmacology/Mechanism of Potent, mechanism-based inhibitor of the P450 CYP3A family. Action Molecular weight 776.02. Activity Cobicistat has no detectable antiviral activity in cell culture against HIV-1, HBV, or HCV and does not antagonize the antiviral activity of elvitegravir, emtricitabine, or tenofovir. Effect of Food When administered as a fixed dose combination tablet (elvitegravir 150 mg, emtricitabine 200 mg, tenofovir 300 mg, cobicistat 150 mg) in healthy volunteers, cobicistat AUC inf and Cmax each ↑ 3% with a light meal, and ↓ 17% and 24% respectively with a high-fat meal. NB: elvitegravir AUC inf and Cmax ↑ by 34% and 22%, respectively, with a light meal and by 87% and 56% with a high-fat meal.[German et al. 2010] Take cobicistat with food. Protein Binding 97-98% Mean blood:plasma ratio is approximately 0.5. Vd 77 L Tmax 3 hours serum T ½ 3.5 hours (when administered as Stribild®) Drug Concentrations Following oral administration, systemic exposure is almost exclusively parent drug. When administered as a fixed dose combination (elvitegravir 150 mg, emtricitabine 200 mg, tenofovir 300 mg, cobicistat 150 mg) in HIV-infected subjects, mean cobicistat AUC 8.3 ± 3.8 ug.h/mL, Ctrough 0.05 ± 0.13 ug/mL, Cmax 1.1 ± 0.4 ug/mL. When administered as a single agent 150 mg tablet formulation, mean cobicistat AUC 11788.86 ng.h/mL, Ctau 58.29 ng/mL, Cmax 1557.73 ng/mL.
    [Show full text]
  • SYMTUZA™ (Darunavir, Cobicistat, Emtricitabine, Tenofovir Alafenamide) Oral
    PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 9/20/2018 SECTION: DRUGS LAST REVIEW DATE: 8/19/2021 LAST CRITERIA REVISION DATE: 8/19/2021 ARCHIVE DATE: SYMTUZA™ (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) oral Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines. The section identified as “Description” defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage. The section identified as “Criteria” defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational. State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity. Pharmacy Coverage Guidelines are subject to change as new information becomes available. For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable.
    [Show full text]
  • Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate
    PATIENT & CAREGIVER EDUCATION Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Stribild Brand Names: Canada Stribild Warning Hepatitis B has gotten worse when this drug was stopped in some people with hepatitis B. Close follow-up for a few months is needed when therapy is stopped in people who have hepatitis B. Do not stop giving this drug to your child without calling your child’s doctor. Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate 1/10 What is this drug used for? It is used to treat HIV infection. What do I need to tell the doctor BEFORE my child takes this drug? If your child is allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell the doctor about the allergy and what signs your child had. If your child has any of these health problems: Kidney disease or liver disease. If your child takes any drugs (prescription or OTC, natural products, vitamins) that must not be taken with this drug, like certain drugs that are used for high cholesterol, migraines, or mood problems. There are many drugs that must not be taken with this drug. If your child is taking any other drugs to treat HIV. If your child is taking another drug that has the same drug in it. If your child is pregnant: Do not give this drug to your child during pregnancy.
    [Show full text]
  • Therapeutic Guidelines for Antiretroviral (ARV) Treatment of Adult HIV Infection September 2015
    Therapeutic Guidelines for Antiretroviral (ARV) Treatment of Adult HIV Infection September 2015 Prepared by J Montaner (editor), S Guillemi and M Harris (co-editors) on behalf of the Committee for Drug Evaluation and Therapy, British Columbia Centre for Excellence in HIV/AIDS The BC-CfE Therapeutic Guidelines have remained generally consistent but not identical with the IAS-USA Guidelines since 1996. The current Guidelines are consistent with those published by H.F. Günthard et al. in 2014 (Günthard HF, Aberg JA, Eron JJ, et al. Antiretroviral Treatment of Adult HIV Infection: 2014 Recommendations of the International Antiviral Society–USA Panel. JAMA 2014; 312(4):410-425). However, the reader should be aware that the use of antiretroviral drugs for the treatment of HIV infection within the BC-CfE programs is exclusively guided by the 2015 Guidelines as outlined here. BC-CfE 2015 ARV Guidelines Page: 2 Committee for Drug Evaluation and Therapy of the BC Centre for Excellence in HIV/AIDS Co-chairs Rolando Barrios Val Montessori Committee Members Linda Akagi Silvia Guillemi Marianne Harris Robert Hogg Mark Hull Deborah Money David Moore Peter Phillips Neora Pick BC-CfE 2015 ARV Guidelines Page: 3 TABLE OF CONTENTS Glossary of abbreviations……………………………………………………………………….….…………….5 I. Summary…………………………………………….…………………………………………………….……...………7 II. Introduction…………………………………………………………………………………………………..……….…9 III. When to start…………………………………………………………………………………………………………..10 A. Recommendations ……………………………………………………………………………………………10 B. Evidence…………………………………………………………………………………………………….……..10
    [Show full text]
  • Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide Monograph
    Elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide Monograph Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®) National Drug Monograph March 2016 VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives The purpose of VA PBM Services drug monographs is to provide a focused drug review for making formulary decisions. Updates will be made when new clinical data warrant additional formulary discussion. Documents will be placed in the Archive section when the information is deemed to be no longer current. FDA Approval Information1,2 Description/Mechanism of Genvoya® is a fixed-dose combination of elvitegravir/cobicistat/ Action emtricitabine/tenofovir alafenamide. Elvitegravir is an integrase strand inhibitor (INSTI), cobicistat is a CYP3A inhibitor (used to increase elvitegravir levels), and emtricitabine and tenofovir are nucleoside analog reverse transcriptase inhibitors (NRTIs). The individual components elvitegravir, cobicistat, and emtricitabine have previously been approved by the FDA. Tenofovir alafenamide is a new molecular entity currently available only in this combination product. A similar fixed-dose combination containing elvitegravir, cobicistat, emtricitabine, and another salt form of tenofovir, tenofovir disoproxil fumarate, is currently available as Stribild®. Tenofovir alafenamide is a prodrug of tenofovir. Intracellularly, tenofovir is phosphorylated to the active moiety, tenofovir-diphosphate which is the same active moiety of tenofovir disoproxil fumarate. While intracellular tenofovir-diphosphate is responsible for antiviral activity, high plasma levels of tenofovir have been associated with renal and bone toxicity. Tenofovir alafenamide has been shown to be more stable in plasma with much higher intracellular levels of tenofovir-diphosphate. As a result, tenofovir alafenamide is dosed at 10mg compared to tenofovir disoproxil fumarate at 300mg.
    [Show full text]
  • PREZCOBIX-Pi.Pdf
    PREZCOBIX® PREZCOBIX (darunavir and cobicistat) tablets (darunavir and cobicistat) tablets, for oral use • Skin reactions ranging from mild to severe, including Stevens-Johnson Highlights of Prescribing Information Syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic These highlights do not include all the information needed to use PREZCOBIX symptoms and acute generalized exanthematous pustulosis, can occur with safely and effectively. See full prescribing information for PREZCOBIX. PREZCOBIX. Discontinue treatment if severe reaction develops. (5.2) PREZCOBIX® (darunavir and cobicistat) tablets, for oral use • When PREZCOBIX is used in combination with a tenofovir disoproxil fumarate Initial U.S. Approval: 2015 (tenofovir DF) containing regimen, cases of acute renal failure and Fanconi syndrome have been reported. (5.4) --------------------------------RECENT MAJOR CHANGES--------------------------------- • PREZCOBIX is not recommended in combination with other antiretroviral drugs Warnings and Precautions, that require pharmacokinetic boosting. (5.6) Risk of Serious Adverse Reactions or Loss of • Monitor in patients with a known sulfonamide allergy. (5.7) Virologic Response Due to Drug Interactions (5.5) 12/2020 • Patients receiving PREZCOBIX may develop new onset or exacerbations of --------------------------------INDICATIONS AND USAGE--------------------------------- diabetes mellitus/hyperglycemia (5.8), redistribution/accumulation of body fat PREZCOBIX is a two-drug combination of darunavir, a human immunodeficiency
    [Show full text]